GEN Exclusives

More »

GEN News Highlights

Back to Item »

Targacept Gets $20M as AstraZeneca Continues with Alzheimer’s Candidate Development

AstraZeneca will continue Phase II trials on AZD3480 to treat Alzheimer’s disease and cognitive deficits in schizophrenia.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?